vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and Life360, Inc. (LIF). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $146.0M, roughly 1.9× Life360, Inc.). Life360, Inc. runs the higher net margin — 88.8% vs -45.7%, a 134.5% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 26.4%). Life360, Inc. produced more free cash flow last quarter ($36.6M vs $-54.2M). Over the past eight quarters, Life360, Inc.'s revenue compounded faster (36.6% CAGR vs 29.2%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
Life360, Inc. develops family-focused safety and connectivity platforms. Core offerings include real-time location sharing, emergency alerts, driving behavior analysis tools and identity theft protection. It serves consumer markets across North America, Europe and Asia-Pacific, with most revenue from tiered premium subscription plans.
GH vs LIF — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $146.0M |
| Net Profit | $-128.5M | $129.7M |
| Gross Margin | 64.6% | 75.1% |
| Operating Margin | -43.0% | 6.1% |
| Net Margin | -45.7% | 88.8% |
| Revenue YoY | 39.4% | 26.4% |
| Net Profit YoY | -15.8% | 1425.9% |
| EPS (diluted) | $-1.01 | $1.53 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $281.3M | $146.0M | ||
| Q3 25 | $265.2M | $124.5M | ||
| Q2 25 | $232.1M | $115.4M | ||
| Q1 25 | $203.5M | $103.6M | ||
| Q4 24 | $201.8M | $115.5M | ||
| Q3 24 | $191.5M | $92.9M | ||
| Q2 24 | $177.2M | $84.9M | ||
| Q1 24 | $168.5M | $78.2M |
| Q4 25 | $-128.5M | $129.7M | ||
| Q3 25 | $-92.7M | $9.8M | ||
| Q2 25 | $-99.9M | $7.0M | ||
| Q1 25 | $-95.2M | $4.4M | ||
| Q4 24 | $-111.0M | $8.5M | ||
| Q3 24 | $-107.8M | $7.7M | ||
| Q2 24 | $-102.6M | $-11.0M | ||
| Q1 24 | $-115.0M | $-9.8M |
| Q4 25 | 64.6% | 75.1% | ||
| Q3 25 | 64.7% | 78.0% | ||
| Q2 25 | 65.0% | 78.4% | ||
| Q1 25 | 63.3% | 80.6% | ||
| Q4 24 | 61.6% | 74.0% | ||
| Q3 24 | 61.1% | 75.4% | ||
| Q2 24 | 59.1% | 75.0% | ||
| Q1 24 | 61.2% | 76.7% |
| Q4 25 | -43.0% | 6.1% | ||
| Q3 25 | -37.3% | 4.6% | ||
| Q2 25 | -45.9% | 1.7% | ||
| Q1 25 | -54.6% | 2.1% | ||
| Q4 24 | -62.4% | 4.9% | ||
| Q3 24 | -61.3% | -5.3% | ||
| Q2 24 | -56.8% | -2.8% | ||
| Q1 24 | -59.2% | -8.2% |
| Q4 25 | -45.7% | 88.8% | ||
| Q3 25 | -35.0% | 7.9% | ||
| Q2 25 | -43.0% | 6.1% | ||
| Q1 25 | -46.8% | 4.2% | ||
| Q4 24 | -55.0% | 7.4% | ||
| Q3 24 | -56.3% | 8.3% | ||
| Q2 24 | -57.9% | -12.9% | ||
| Q1 24 | -68.2% | -12.5% |
| Q4 25 | $-1.01 | $1.53 | ||
| Q3 25 | $-0.74 | $0.11 | ||
| Q2 25 | $-0.80 | $0.08 | ||
| Q1 25 | $-0.77 | $0.05 | ||
| Q4 24 | $-0.90 | $0.14 | ||
| Q3 24 | $-0.88 | $0.09 | ||
| Q2 24 | $-0.84 | $-0.15 | ||
| Q1 24 | $-0.94 | $-0.14 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $494.3M |
| Total DebtLower is stronger | $1.5B | — |
| Stockholders' EquityBook value | $-99.3M | $548.2M |
| Total Assets | $2.0B | $959.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $378.2M | $494.3M | ||
| Q3 25 | $580.0M | $455.7M | ||
| Q2 25 | $629.1M | $432.7M | ||
| Q1 25 | $698.6M | $168.9M | ||
| Q4 24 | $525.5M | $159.2M | ||
| Q3 24 | $585.0M | $159.0M | ||
| Q2 24 | $933.7M | $160.8M | ||
| Q1 24 | $1.0B | $73.4M |
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $5.2M |
| Q4 25 | $-99.3M | $548.2M | ||
| Q3 25 | $-354.5M | $391.4M | ||
| Q2 25 | $-305.5M | $366.7M | ||
| Q1 25 | $-250.8M | $376.3M | ||
| Q4 24 | $-139.6M | $358.5M | ||
| Q3 24 | $-60.1M | $339.7M | ||
| Q2 24 | $-1.6M | $326.7M | ||
| Q1 24 | $68.3M | $239.8M |
| Q4 25 | $2.0B | $959.7M | ||
| Q3 25 | $1.3B | $787.5M | ||
| Q2 25 | $1.3B | $753.6M | ||
| Q1 25 | $1.3B | $455.4M | ||
| Q4 24 | $1.5B | $441.6M | ||
| Q3 24 | $1.5B | $427.4M | ||
| Q2 24 | $1.6B | $405.9M | ||
| Q1 24 | $1.7B | $318.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.02× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $36.8M |
| Free Cash FlowOCF − Capex | $-54.2M | $36.6M |
| FCF MarginFCF / Revenue | -19.3% | 25.1% |
| Capex IntensityCapex / Revenue | 9.9% | 0.2% |
| Cash ConversionOCF / Net Profit | — | 0.28× |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | $86.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.4M | $36.8M | ||
| Q3 25 | $-35.4M | $26.4M | ||
| Q2 25 | $-60.3M | $13.3M | ||
| Q1 25 | $-62.7M | $12.1M | ||
| Q4 24 | $-64.5M | $12.3M | ||
| Q3 24 | $-51.1M | $6.3M | ||
| Q2 24 | $-94.0M | $3.3M | ||
| Q1 24 | $-30.3M | $10.7M |
| Q4 25 | $-54.2M | $36.6M | ||
| Q3 25 | $-45.8M | $25.6M | ||
| Q2 25 | $-65.9M | $12.7M | ||
| Q1 25 | $-67.1M | $11.9M | ||
| Q4 24 | $-83.4M | $11.2M | ||
| Q3 24 | $-55.3M | $6.3M | ||
| Q2 24 | $-99.1M | $3.2M | ||
| Q1 24 | $-37.2M | — |
| Q4 25 | -19.3% | 25.1% | ||
| Q3 25 | -17.3% | 20.6% | ||
| Q2 25 | -28.4% | 11.0% | ||
| Q1 25 | -33.0% | 11.5% | ||
| Q4 24 | -41.3% | 9.7% | ||
| Q3 24 | -28.9% | 6.8% | ||
| Q2 24 | -55.9% | 3.8% | ||
| Q1 24 | -22.1% | — |
| Q4 25 | 9.9% | 0.2% | ||
| Q3 25 | 3.9% | 0.6% | ||
| Q2 25 | 2.4% | 0.6% | ||
| Q1 25 | 2.2% | 0.1% | ||
| Q4 24 | 9.4% | 1.0% | ||
| Q3 24 | 2.2% | 0.0% | ||
| Q2 24 | 2.9% | 0.1% | ||
| Q1 24 | 4.1% | 0.0% |
| Q4 25 | — | 0.28× | ||
| Q3 25 | — | 2.70× | ||
| Q2 25 | — | 1.90× | ||
| Q1 25 | — | 2.75× | ||
| Q4 24 | — | 1.45× | ||
| Q3 24 | — | 0.83× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
LIF
Segment breakdown not available.
